Jasper Therapeutics, Inc. JSPR 深 沪
已收盘 08-07 16:00:00 美东时间
0.7095
+0.063
+9.81%
华盛通- 最 高0.75
- 今 开0.6515
- 成交量 75.72万股
- 最 低 0.5901
- 昨 收 0.6461
- 总市值 2.69万
- 52周最高 3.13
- 市盈率 静 --
- 换手率 1999.11%
- 52周最低 0.3151
- 委 比 -6.73%
- 总股本 3.79万
- 历史最高 31.01
- 量 比 1.39
- 振 幅 24.75%
- 历史最低 0.3151
- 每 手 1
- 风险率 0.75%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Jasper Closes Kira Deal, Extends Cash Runway
Jasper Therapeutics (JSPR) acquires Kira Pharma & raises $132M, extending its cash runway into 2028. Shares surge 20%+.
07-18 01:08
TD Cowen Downgrades Jasper Therapeutics to Hold
TD Cowen analyst Yaron Werber downgrades Jasper Therapeutics (NASDAQ:JSPR) from Buy to Hold.
05-16 00:45
Jasper Stock Jumps After Promising New Asthma Study Results
Jasper Therapeutics released positive data from a study of subcutaneous briquilimab for allergic asthma treatment.
2025-12-03 00:14
Market-Moving News for December 2nd
MDB: 24% | MongoDB shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY26 guidance above estimates. Also, the company issued Q4 guidance above
2025-12-02 20:12
CoreWeave Bulls Should Brace For 'Wild, Lumpy, Volatile Ride,' JPMorgan Says
JPMorgan downgrades CoreWeave, citing turbulence in AI infrastructure market. Despite near-term challenges, long-term growth...
2025-11-11 22:03
Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
Jasper Therapeutics' briquilimab shows strong efficacy in treating chronic inducible urticaria, with 92% achieving complete response and 100% clinical response in the 180mg cohort. No serious adverse events were reported, supporting its safety and potential as a novel treatment.
2025-06-14 14:00
Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress
Jasper Therapeutics highlights its four abstracts accepted at EAACI Congress 2025, showcasing briquilimab's initial clinical data in treating mast cell-driven diseases like chronic urticaria and asthma. Presentations focus on briquilimab's efficacy in cold urticaria, dermatographism, CSU, and asthma models.
2025-06-03 12:00
Cantor Fitzgerald Reiterates Overweight on Jasper Therapeutics
Cantor Fitzgerald analyst Josh Schimmer reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Overweight.
2024-09-10 01:12
JMP Securities Initiates Coverage On Jasper Therapeutics with Market Outperform Rating, Announces Price Target of $70
JMP Securities analyst Silvan Tuerkcan initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Market Outperform rating and announces Price Target of $70.
2024-09-09 18:02
